Double-blind, randomized, placebo-controlled, parallel-group study of AP30663 administered intravenously for cardioversion in patients with atrial fibrillation
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: SYNEOS HEALTH IVH UK LIMITED (FORMERLY INVENTIV HEALTH CLINICAL UK LTD),
- Phase: II
- Execution start: 24/06/2019
- End of execution: 30/12/2020
- IP: LUIS TERCEDOR SANCHEZ